依瓦布拉定
医学
心力衰竭
心脏病学
心率
内科学
窦房结
窦性心律
食品药品监督管理局
药品
心肌病
重症监护医学
药理学
心房颤动
血压
作者
Pallavi Choudhary,Mohsin Ansari,Murtaza Kamal
标识
DOI:10.1016/j.ppedcard.2020.101333
摘要
Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on sinoatrial node, resulting in a reduction in heart rate [1]. The Food and Drug Administration (FDA) has approved use of Ivabradine for treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate. Ivabradine is a new drug for use in pediatric age group. In this review article we examine the mechanism of action of Ivabradine, evaluate the clinical trials underpinning its application in heart failure and we shall also discuss its other uses in other heart conditions in pediatric age group and its current recommendations.
科研通智能强力驱动
Strongly Powered by AbleSci AI